Changing Diabetes
Novo Nordisk is dedicated to changing diabetes - how it is treated, how it is viewed around the world, and how the future of this disease plays out.
As a world leader in diabetes care, Novo Nordisk sees this as part of the company’s responsibility—and a goal that cannot be achieved through science alone. It requires change at every level—in science and research, in care provision, in humanitarianism and outreach efforts, in education, and in government and public policy worldwide. Novo Nordisk is committed to taking a global leadership role in changing diabetes.
Performance 2007
Leadership Forum
In 2007, Novo Nordisk took steps, as part of its changing diabetes leadership initiative, to bring diabetes higher up on the political agendas; showing the way for sustainable health policy and systems change; and encouraging national action that works.
As part of its collaborative, multi-stakeholder approach to changing diabetes, Novo Nordisk held the first Global Changing Diabetes Leadership Forum in March 2007. The forum’s ambition was to translate the UN Resolution on Diabetes, adopted by the United Nations General Assembly in December 2006, into national action plans.
Keynote speaker at the Forum was former US President Bill Clinton. The forum was attended by some 150 representatives of governments, international organisations, patient organisations, healthcare professionals, academia and media from 21 countries.
Changing Diabetes Barometer
Another leadership initiative is the Global Changing Diabetes Barometer, launched on 7 November 2007 at a global press conference in Brussels.
The Barometer is a tool that identifies diabetes indicators (such as the HbA1c test of blood-sugar level) using published data. It aims to provide a scorecard for tracking change and pinpointing areas in need of improvement, so that healthcare providers, governments, and patient associations are better able to measure progress and set priorities for national diabetes action plans.
The first Barometer report issued in 2007 covered 21 countries. It highlights that lifelong healthcare costs can be reduced by as much as 20%, if people with diabetes are diagnosed earlier and before any complications arise.
The Barometer is Novo Nordisk’s response to the call for action that followed the December 2006 passage of the United Nations Resolution on Diabetes, which urges governments to develop national policies for the prevention, treatment and care of diabetes.
This page has been reviewed by PricewaterhouseCoopers as part of its assurance of Novo Nordisk’s non-financial reporting. Please refer to Audit and assurance for a full description of the conclusions and the nature of assurance offered.
